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1.1. Anatomy
1.1.1. Primary site
The upper two-thirds of the uterus above the level of the internal
cervical os is called the corpus. The fallopian tubes enter at theupper lat-
eral corners of a pear-shaped body. The portion of the muscular organ
that is above a line joining the tubo-uterine oriﬁces is often referred to
as the fundus.
1.1.2. Nodal stations
The major lymphatic trunks are the utero-ovarian (infundibu-
lopelvic), parametrial, and presacral, which drain into the hypogastric,
external iliac, common iliac, presacral, and para-aortic nodes. Although
a direct route of lymphatic spread from the corpus uteri to the para-
aortic nodes through the infundibulopelvic ligament has been sug-
gested from anatomical and sentinel lymph node studies, direct metas-
tases to the para-aortic lymph nodes are uncommon.
1.1.3. Metastatic sites
The vagina and lungs are the common metastatic sites.
1.2. Rules for classiﬁcation
The FIGO Committee on Gynecologic Oncology, following its
meeting in 1988, recommended that endometrial cancer be surgically
staged. There should be histologic veriﬁcation of grading and extent of
the tumor.
1.3. Histopathology
1.3.1. Histopathologic types (according to World Health Organization/
International Society of Gynecological Pathology classiﬁcation)
All tumors are to be microscopically veriﬁed.
The histopathologic types are:
• Endometrioid carcinoma: adenocarcinoma; adenoacanthoma (adeno-
carcinomawith squamousmetaplasia); and adenosquamous carcino-
ma (mixed adenocarcinoma and squamous cell carcinoma).
• Mucinous adenocarcinoma.http://dx.doi.org/10.1016/j.ijgo.2015.06.005
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).• Serous adenocarcinoma.
• Clear cell adenocarcinoma.
• Undifferentiated carcinoma.
• Mixed carcinoma (carcinoma composed of more than one type, with
at least 10% of each component).
Endometrial cancers are usually classiﬁed in one of the following
two categories:
• Type 1 (grade 1 and 2 endometrioid carcinoma) may arise from
complex atypical hyperplasia and is linked to unopposed estro-
genic stimulation.
• Type 2 includes grade 3 endometrioid tumors aswell as tumors of non-
endometrioid histology and develops from atrophic endometrium.
1.3.2. Histopathologic grades (G)
• GX: Grade cannot be assessed.
• G1: Well differentiated.
• G2: Moderately differentiated.
• G3: Poorly or undifferentiated.
Cases of carcinoma of the corpus should be grouped with regard to
the degree of differentiation of the adenocarcinoma as follows:
• G1: less than5%of a nonsquamous or nonmorular solid growthpattern.
• G2: 6%–50% of a nonsquamous or nonmorular solid growth pattern.
• G3: greater than 50% of a nonsquamous or nonmorular solid
growth pattern.
1.3.3. Pathologic grading notes
Notable nuclear atypia (pleomorphism and prominent nucleoli), in-
appropriate for the architectural grade, raises the grade of a grade 1 or
grade 2 tumor by 1.
In serous and clear cell adenocarcinomas, nuclear grading takes pre-
cedent. Most authors consider serous and clear cell carcinomas high
grade by deﬁnition.
Adenocarcinomas with squamous differentiation are graded accord-
ing to the nuclear grade of the glandular component.Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
Table 2
Cancer of the corpus uteri: FIGO staging compared with the TNM classiﬁcation.a
FIGO Stage Union for International Cancer Control (UICC)
T
(tumor)
N
(lymph nodes)
M
(metastasis)
I T1 N0 M0
IA T1a N0 M0
IB T1b N0 M0
II T2 N0 M0
III T3 N0–N1 M0
IIIA T3a N0 M0
IIIB T3b N0 M0
IIIC1 T1–T3 N1 M0
IIIC2 T1–T3 N1 M0
IVA T4 Any N M0
IVB Any T Any N M1
a Carcinosarcomas should be staged as carcinoma.
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The current FIGO staging classiﬁcation for cancer of the corpus uteri
is given in Table 1. Comparison of the stage groupings with the TNM
classiﬁcation is given in Table 2.
1.4.1. Regional lymph nodes (N)
• NX: Regional lymph nodes cannot be assessed.
• N0: No regional lymph node metastasis.
• N1: Regional lymph node metastasis to pelvic lymph nodes.
• N2: Regional lymph nodemetastasis to para-aortic lymph nodes, with
or without positive pelvic lymph nodes.
1.4.2. Distant metastasis (M)
• MX: Distant metastasis cannot be assessed.
• M0: No distant metastasis.
• M1: Distant metastasis (includes metastasis to inguinal lymph nodes
or intraperitoneal disease).
1.4.3. Rules related to staging
Corpus cancer is surgically staged, therefore procedures previously
used for determination of stage are no longer applicable (e.g. the ﬁnd-
ings of fractional curettage to differentiate between Stage I and Stage II).
There may be a small number of patients with corpus cancer who
will be treated primarily with radiation therapy. In these cases, the clin-
ical staging adopted by FIGO in 1971 would still apply, but designation
of that staging system should be noted.
Ideally, distance from tumor to serosa should be measured. The
presence of lymphovascular space invasion (LVSI) should also be re-
ported in the pathological report of the hysterectomy specimen. A
LVSI-positive status has a signiﬁcantly worse prognosis, especially if ex-
tensive LVSI is found [1]. The distinction by LVSI status could be more
relevant than the distinction between Stages IA and IB for predicting
survival in Stage I endometrial cancer [2].
As a minimum, any enlarged or suspicious lymph nodes should
be removed in all patients. For high-risk patients (grade 3, deep
myometrial invasion, cervical extension, serous or clear cell histology),
complete pelvic lymphadenectomy and resection of any enlarged
para-aortic nodes is recommended.Table 1
Cancer of the corpus uteri.
FIGO
Stage
Ia Tumor conﬁned to the corpus uteri
IAa No or less than half myometrial invasion
IBa Invasion equal to or more than half of the myometrium
IIa Tumor invades cervical stroma, but does not extend beyond the
uterus b
IIIa Local and/or regional spread of the tumor
IIIAa Tumor invades the serosa of the corpus uteri and/or adnexaec
IIIBa Vaginal involvement and/ or parametrial involvementc
IIICa Metastases to pelvic and/or para-aortic lymph nodesc
IIIC1a Positive pelvic nodes
IIIC2a Positive para-aortic nodes with or without positive pelvic lymph nodes
IVa Tumor invades bladder and/or bowel mucosa, and/or distant
metastases
IVAa Tumor invasion of bladder and/or bowel mucosa
IVBa Distant metastasis, including intra-abdominal metastases and/or
inguinal nodes)
a Either G1, G2, or G3.
b Endocervical glandular involvement only should be considered as Stage I and no lon-
ger as Stage II.
c Positive cytology has to be reported separately without changing the stage.2. Introduction
Worldwide, endometrial cancer is the sixth most common malig-
nant disorder with approximately 290 000 new cases annually. The
incidence is higher in high-income countries (5.5%) compared with
low-income countries (4.2%), although speciﬁc mortality is higher in
the latter. The cumulative risk of endometrial cancer up to the age of
75 years has been estimated as 1.6% for high-income regions and 0.7%
for low-income countries [3]. This difference has been associated with
an epidemic of obesity and physical inactivity, two important risk fac-
tors, in high-income countries. Moreover, endometrial cancer patients
with obesity also tend to have a poorer outcome [4]. On the other
hand, physical activity and long-term use of continuous combined
estrogen–progestin therapy is associated with a reduced risk of endo-
metrial cancer [4,5]. Obesity is associated with earlier age at diagnosis,
and with endometrioid-type endometrial cancers. Similar associations
were not observed with nonendometrioid cancers, consistent with dif-
ferent pathways of tumorigenesis [6].
In North America and Europe, endometrial cancer is the most
frequent cancer of the female genital tract and the fourthmost common
site after breast, lung, and colorectal cancer [3]. The incidence is rising as
life expectancy increases. Furthermore, an estimated 23 700 European
women died of endometrial cancer in 2012, which is the eighth most
common cause of death from cancer in women [7]. Importantly, the
corrected corpus uteri cancer mortality rates showed a decrease in
most European Union member states among women born before
1940 [8].
In North America, it is the seventh most frequent cause of death,
with approximately 55 000 new cases and 10 000 estimated newdeaths
each year [3]. The increase in endometrial cancer incidence rates
after 2002 may be related to the widespread decrease in estrogen
plus progestin menopausal hormone therapy use, which has been
reported to lower endometrial cancer risk in overweight and obese
women [9]. However, the main reasons underlying the increase in en-
dometrial cancer incidence in high-income countries remain the
increasing prevalence of obesity in postmenopausal as well as the in-
creased life expectancy.
Endometrioid adenocarcinoma progresses through a premalignant
phase of intraepithelial endometrial neoplasia in a large proportion of
cases [10]. Other forms such as serous and clear cell carcinoma arise as
a result of a sequence of genetic mutations. In serous endometrial can-
cer, the mutant p53 plays a pivotal role [11]. Endometrial cancer re-
search has gained some momentum in recent years and now provides
better information for clinical practice. Its early presentation following
postmenopausal bleeding results in a generally good prognosis, but it
should be treated using evidence-based protocols, andwhere appropri-
ate, by expert multidisciplinary teams.
The role of population screening for endometrial cancer remains low
[12], although certain high-risk groups such as those with Lynch type 2
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vaginal ultrasonography if post menopausal. Transvaginal ultrasound
is reasonably sensitive and speciﬁc but screening of asymptomatic
women has in general been recommended only for those with Lynch
syndrome [13].
Following presentation, ultrasound is an effective ﬁrst test with a
high negative predictive value when the endometrial thickness is less
than 5 mm. In one of the largest studies undertaken, there was a nega-
tive predictive value of 96% among 1168women in whom the results of
transvaginal ultrasound were correlated with an endometrial biopsy
obtained by curettage [14]. When a biopsy is required, this can be ob-
tained usually as an ofﬁce procedure using a number of disposable in-
struments developed for this purpose. In certain cases, hysteroscopy
may be helpful, and with ﬂexible instruments can also be done without
recourse to general anesthesia. However, the biological role of cells that
are transtubally ﬂushed during hysteroscopy remains uncertain. If cer-
vical stenosis or patient tolerance does not permit an ofﬁce procedure,
hysteroscopy and curettage under anesthesia may be necessary. Indi-
viduals whose pelvic examination is unsatisfactorymay also be evaluat-
ed with transvaginal or abdominal ultrasound to rule out concomitant
adnexal pathology.
Following a histopathologic diagnosis of endometrial adenocar-
cinoma, the local extent of the tumor, and evidence of metastatic dis-
ease should be determined. In addition, the perioperative risk should
be assessed.
As a minimum, the pathology report from endometrial sampling
should indicate the tumor type and grade of the lesion. A chest X-ray,
full biochemistry (renal and liver function tests), and blood count are
routine. A serum CA125 may be of value in advanced disease for
follow-up. Evaluation for metastasis is indicated particularly in patients
with abnormal liver function tests, and clinical ﬁndings such as
parametrial or vaginal tumor extension. In high-risk patients, imaging
of the abdomen and lymph nodes may help determine the surgical
approach. In certain situations, cystoscopy and/or proctoscopy/barium
enema may be helpful if direct extension to the bladder or rectum
is suspected.
3. Prognostic tumor characteristics for high-risk disease
The recommended histopathologic criteria for determining high-
risk disease are:
• Tumor grade 3 (poorly differentiated).
• More than 50% of myometrial invasion.
• Lymphovascular space invasion.
• Non-endometrioid histology (serous, clear cell, undifferentiated,
small cell, anaplastic, etc.).
• Cervical stromal involvement.
The most accurate means of assessing both depth of myometrial in-
vasion and cervical involvement is MRI scanning and intraoperative
frozen section [15–17]. CT andMRI are equivalent in terms of evaluating
nodal metastases, but neither is good enough to replace surgical lymph
node assessment, which provides histological conﬁrmation [18,19]. The
role of PET-CT and PET-MRI is currently being investigated.
Nonsurgical staging for endometrial cancer, where extrauterine dis-
ease exists, is inherently inaccurate, particularly in respect to small
nodal involvement, intraperitoneal implants, and adnexal metastasis.
4. Surgical staging procedure for endometrial cancer
In 1988, the FIGO Cancer Committee changed the ofﬁcial FIGO stag-
ing from clinical to surgical for endometrial cancer. Since that recom-
mendation, considerable debate has ensued as to what constitutes an
internationally acceptable approach. A generally recommended proto-
col would be that the abdomen should be opened with a verticalmidline abdominal incision and peritoneal washings taken immediately
from the pelvis and abdomen, followed by careful exploration of the
intra-abdominal contents. The omentum, liver, peritoneal cul-de-sac,
and adnexal surfaces should be examined and palpated for any possible
metastases, followed by careful palpation for suspicious or enlarged
nodes in the aortic and pelvic areas. The standard surgical procedure
should be an extrafascial total hysterectomy with bilateral salpingo-
oophorectomy. Adnexal removal is recommended even if the tubes
and ovaries appear normal, as they may contain micrometastases.
Vaginal cuff removal is not necessary, nor is there any beneﬁt from
excising parametrial tissue in the usual case. Where obvious cervical
stromal involvement is demonstrated preoperatively, amodiﬁed radical
hysterectomy has been historically performed. However, there is
consensus (ESMO-ESGO-ESTRO) that simple hysterectomy with free-
margins together with pelvic lymphadenectomy can be sufﬁcient.
There has also been considerable debate on the safety of endoscopic
surgery for the treatment of endometrial cancer. Recent studies have
demonstrated that laparoscopic removal of the uterus and adnexae
(in experienced hands) appears to be safe. Whereas there is no differ-
ence in terms ofmajor complications between abdominal hysterectomy
and laparoscopically assisted vaginal hysterectomy (LAVH) or total lap-
aroscopic hysterectomy (TLH), the laparoscopic approach is associated
with a signiﬁcantly decreased risk of major surgical adverse event, a
shorter hospital stay, less pain, and quicker resumption of daily activi-
ties [20–22]. Since the oncological safety of the laparoscopic approach
has nowbeen demonstrated in several randomized studies [23,24], hys-
terectomy and bilateral salpingo-oophorectomy should be performed
with laparoscopy in those patientswith no contraindications to laparos-
copy (e.g. large-volumeuterus). This approach can be accompanied by a
laparoscopic lymphadenectomy, if surgical staging is to be undertaken.
Robotic surgery for the surgical management of the morbidly obese pa-
tient is an option only in experienced hands. In such cases, the surgical
management using robotics has been reported to be safe and have
less perioperative complications compared with open surgery [25].
Retrospective studies have suggested equivalent oncologic outcomes
compared with traditional laparoscopic surgery [26,27].
Although mandated through the staging system, lymphadenectomy
of the pelvic and para-aortic areas remains controversial. Selective node
sampling is of dubious value as a routine and complete lymphadenecto-
my should be reserved for cases with high-risk features. Many individ-
uals with endometrial cancer are obese or elderly, with other medical
problems, and clinical judgment is required to determine if additional
surgery is warranted. Any deeply invasive tumor or radiological sugges-
tion of positive nodes is an indication for retroperitoneal lymph
node evaluation, with removal of any enlarged or suspicious nodes.
Documentation of positive nodes identiﬁes a high-risk population and
helps to tailor adjuvant treatment, since patients with Stage III disease
appear to beneﬁt from chemotherapy [28].
Indications for aortic node samplingwould include suspicious aortic
or common iliac nodes, grossly positive adnexae, grossly positive pelvic
nodes, and high-grade tumors showing full thickness myometrial inva-
sion. Patients with clear cell, papillary serous, or carcinosarcoma histo-
logic subtypes are also candidates for aortic node sampling.
5. Who should perform the surgery?
Low-risk tumors will have positive nodes in less than 5% of cases
(well differentiated and b1/2 myometrial invasion) and do not require
full surgical staging. Thesewomen can be safely operated on by a gener-
al gynecologist, but those at greater risk of extrauterine disease, who
may require lymphadenectomy, should be referred to a gynecological
oncologist since care provided by gynecologic oncologists has been as-
sociatedwith better survival in high-risk cancers [29]. Moreover, prima-
rymanagement by gynecologic oncologists has been suggested to result
in an efﬁcient use of health care resources and minimization of the po-
tential morbidity associated with adjuvant radiation [30].
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preoperative assessment, paying particular attention to the pathology
and to radiological features. Triaging for lymphadenectomy is also pos-
sible during surgery. Intraoperative assessment mainly involves assess-
ment of myometrial invasion [15,17,27]. Grading on frozen section is
possible, though suboptimal compared with preoperative grading [17].
6. When should surgery be performed?
The effect of waiting time for surgical staging on survival outcome of
endometrial cancer is controversial. A recent population-based study
concluded that a longer waiting time for surgical stagingwas associated
with worse survival outcomes in uterine cancer [31]. However, when
focusing on type I endometrial cancer only, thewaiting time for surgical
staging was not associated with decreased survival outcome, presum-
ably due to its excellent prognosis anyway [32].
7. Is lymphadenectomy therapeutic?
Although required for accurate staging, a therapeutic beneﬁt for
lymphadenectomy is controversial. Historically, one case–control
study suggested that it may be therapeutic [33] and another showed a
good prognosis even in node-positive women [34]. Another retrospec-
tive study showed a survival beneﬁt of complete lymphadenectomy
for patients with grade 3 tumors [35]. In the UK, the MRC ASTEC trial,
however, which randomized 1400 women undergoing surgery for pre-
sumed Stage I endometrial cancer to pelvic lymphadenectomy or no
lymphadenectomy, showed no therapeutic beneﬁt [36]. An Italian ran-
domized trial of pelvic (and in 30% para-aortic) lymphadenectomy
versus no lymphadenectomy in 540 women also did not show any dif-
ference in rates of relapse or survival [37]. Both studies have been criti-
cized because of a limited effort with respect to the extent of dissection
and lymph node evaluation, because of the high proportion of low-risk
patients, and because no direct decision on adjuvant therapy based on
lymphadenectomy was part of the protocols. Lymphadenectomy is pri-
marily used for staging and should be considered in women with high-
risk factors [38]. Although a direct survival beneﬁt of lymphadenectomy
has not been documented, the procedure identiﬁes node-positive
patients that may beneﬁt from adjuvant treatment. An international
trial of the role of lymphadenectomy to direct adjuvant therapy
for high-risk endometrial cancer (STATEC) is planned. The ongoing
ENGOT-EN2-DGCG/EORCT 55102 trial aims to answer this question by
comparing survival in patients with Stage I grade 3 endometrioid endo-
metrial cancer, Stage I and II type 2 endometrial cancer or Stage II
endometrioid endometrial cancer and without metastatic node after
randomization for adjuvant chemotherapy.
In a retrospective study, para-aortic lymphadenectomy resulted
in an improved outcome in intermediate and high-risk patients
when compared with pelvic lymphadenectomy alone [39]. However,
adjuvant therapy was not comparable in the two groups. In patients
who underwent both pelvic and para-aortic lymphadenectomy, 77% re-
ceived chemotherapy whereas this was given to only 45% of patients
who underwent pelvic lymphadenectomy alone. This study suggests
both pelvic and para-aortic lymphadenectomy are beneﬁcial in compar-
ison with patients who undergo pelvic lymphadenectomy alone, but it
does not imply that extensive lymphadenectomy improves survival in
comparison with no lymphadenectomy.
8. Adjuvant treatment
Risk factors are used to determine the indication for adjuvant
radiation therapy, as the majority of patients are at low risk of recur-
rence. Low-risk disease (Stage I, grade 1 or 2 with no or superﬁcial
myometrial invasion) does not require adjuvant radiation therapy,
as demonstrated in a Danish cohort study of low-risk women, with
96% ﬁve-year survival after surgery alone [40]. A seminal Norwegiantrial [41], which included 621 women treated after surgery with
vaginal brachytherapy, indicated that overall survivalwas not improved
by additional external beam radiation therapy (EBRT), although it did
reduce the risk of pelvic recurrence. Three large randomized trials of
pelvic radiation therapy versus no further treatment after surgery
have determined the role of radiation therapy based on risk factors,
and have led to reduced indications for adjuvant radiation therapy:
the PORTEC trial [42], the US GOG#99 trial [43], and the UK MRC
ASTEC trial [44]. All of these trials reported a signiﬁcant reduction
in the rates of vaginal and pelvic recurrence with EBRT, but with-
out survival beneﬁt. EBRT added to the risk of long-term morbidity.
PORTEC and ASTEC trials had similar recurrence and survival rates
without lymphadenectomy, compared with GOG#99 that included pa-
tients with documented node-negative disease. PORTEC-1 showed
that most pelvic relapses were located in the vaginal vault (75%), and
that salvage rates were high in women who had not had previous radi-
ation therapy [45].
The PORTEC-2 trial randomized 427womenwith high–intermediate
risk factors to EBRT or vaginal brachytherapy alone [46]. This trial
showed that vaginal brachytherapy had excellent vaginal control rates
(b2% at 5 years for both EBRT and vaginal brachytherapy groups),
with minimal adverse effects and signiﬁcantly better quality of life.
Quality of life of patients in the brachytherapy group remained the
same as those of an age-matched normal population [47]. Vaginal
brachytherapy has replaced EBRT as standard adjuvant treatment for
patients with high–intermediate risk factors.
That omission of any EBRT or vaginal brachytherapy for
(high)intermediate risk disease increases recurrence rates (22%
for intermediate risk disease, of which 15% locoregional) but without
a difference in survival has been conﬁrmed by a Danish population
study [48]. A patient preference study showed that patient’s
preferences are biased to a treatment preventing relapse [49].
The seminal NSGO-9501 trial investigated the use of both EBRT
and adjuvant platinum-based chemotherapy compared with EBRT
alone for patients with risk factors (grade 3 or deep invasion or adverse
histologies). This trial was published in a pooled analysiswith the Italian
ILIADE trial [50]. While trials comparing adjuvant EBRT alone with
adjuvant cisplatin-based chemotherapy alone have not shown any dif-
ference in overall or relapse-free survival [51,52], the pooled NSGO-
EC9501/EORTC55991 and ILIADE trial analysis reported a signiﬁcant
9% improvement in progression-free survival (69% vs 78% at 5 years;
Hazard Ratio [HR] 0.63) with the addition of chemotherapy to EBRT,
and a trend for a 7% improvement in ﬁve-year overall survival (75% vs
82%; HR 0.69, P= 0.07).
Ongoing and recently completed trials are currently investigating
the roles of EBRT or chemotherapy alone or combined EBRT and
chemotherapy for patients with high-risk or advanced stage disease
(GOG#249, GOG#258, PORTEC-3, Danish/EORTC trials). First results of
the randomised GOG-249 trial (601 patients with Stage I− II endome-
trial cancer with high− intermediate or high-risk factors, comparing
vaginal brachytherapy plus three cycles of carboplatin-paclitaxel
with pelvic EBRT) showed no differences in relapse-free survival (84%
vs 82%) or overall survival (92% vs 93%) between the arms at a median
follow-up of 24 months [53]. About 50% of the trial population had
grade 1–2 disease with a baseline ﬁve-year survival of 86%− 91%. In
the PORTEC-3 trial, patients with high-risk Stage I − II or with Stage
III endometrial cancer were randomized to pelvic EBRT alone or EBRT
with two cycles of cisplatin followed by four cycles of carboplatin and
paclitaxel. PORTEC-3 completed accrual (686 patients enrolled) in late
2013 and results are expected in 2016. In the ongoing ENGOT-EN2-
DGCG-trial patients with node-negative endometrial cancer with
high-risk features are randomized to adjuvant chemotherapy (six cycles
of carboplatin-paclitaxel) or observation, with or without brachythera-
py in both arms. These trials will answer many of the questions regard-
ing optimal use and optimal schedules of adjuvant therapy for women
with high-risk endometrial cancer.
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with grade 1–2 tumors and no more than 50% myometrial invasion,
or for those with only a single risk factor. For patients with high–
intermediate risk factors (at least two of the factors: age N60 years,
deep myometrial invasion, grade 3, serous or clear cell histology,
LVSI), vaginal brachytherapy alone is preferable to EBRT, providing ex-
cellent vaginal control without impacting on quality of life. In patients
with higher-risk disease (3 or more risk factors, Stages II and III), the
role of adjuvant chemotherapy, with or without radiation therapy, is
currently being investigated.
9. Progestogen therapy
This has been widely prescribed in the past, but a meta-analysis of
six randomized trials involving a total of 3339 women has shown no
survival beneﬁt for adjuvant progestogen therapy in endometrial cancer
[54]. A subsequently published randomized trial of 1012 women also
failed to demonstrate any survival beneﬁt [55].
10. Stage II
10.1. Occult Stage II disease
Patients with clinically occult Stage II disease are generallymanaged
in a similar way to patients with Stage I disease.
10.2. Clinical overt Stage II disease
Historically, radical hysterectomy, bilateral salpingo-oophorectomy,
bilateral pelvic lymphadenectomy, and selective aortic node dissection
can be used as primary treatment for clinically overt cervical involve-
ment. However, this strategy is poorly supported by the medical litera-
ture. Results from one of the rare retrospective studies could not ﬁnd
any survival beneﬁt from radical hysterectomy for patients with
suspected gross cervical involvement in comparison with simple or
modiﬁed radical hysterectomy [56]. Since radical hysterectomy in-
creases the risk of adverse events, surgical treatment in patients with
suspected gross cervical involvement deserves further prospective eval-
uation. Preoperative MRI scanning is advisable to exclude bladder in-
volvement and ensure local resectability. Studies indicate excellent
results for this approach, with no beneﬁt from the addition of radiation
for patients with negative nodes [57,58]. Adjuvant radiotherapy is usu-
ally reserved for patients with involved nodes and/or close or involved
surgical margins.
However, neoadjuvant therapy followed by a less extensive simple
hysterectomy can represent an alternative.
The need for adjuvant radiotherapy has not been studied in a ran-
domized trial, but a SEER study reported improved survival for patients
with Stage II endometrial cancer when adjuvant radiotherapy was used
after radical and simple hysterectomy [59,60].
If surgery is not considered feasible because of tumor extension, full
pelvic radiotherapy and intracavitary brachytherapy, as in cervical
cancer, may be employed.
11. Stage III
Most patients with Stage III endometrial cancer are managed by
complete surgical resection of all metastatic disease, followed by post-
operative EBRT and/or chemotherapy. The randomized GOG#122 trial
included patients with Stages III and IV disease and residual tumor up
to 2 cm, and compared whole abdominal radiation with intensive
adjuvant chemotherapy (eight cycles of doxorubicin and cisplatin). It
showed a survival beneﬁt for chemotherapy (42% vs 53% estimated
ﬁve-year survival), although event rates were high in both arms [28].
Adjuvant platin-based chemotherapy (more recently, carboplatin
and paclitaxel) is increasingly used to reduce the risk of metastases.Retrospective studies have shown substantial pelvic recurrence rates
when EBRTwas omittedwhen using chemotherapy [61,62], and current
ongoing trials are investigating the roles of chemotherapy, and combi-
nations of chemotherapy and radiation therapy.
A recent meta-analysis including four multicenter randomized con-
trolled trials involving 1269 women with primary FIGO Stage III/IV en-
dometrial cancer who received primary cytoreductive surgery showed
that chemotherapy increases survival time after primary surgery by ap-
proximately 25% relative to radiotherapy [63]. Two trials, evaluating
620 women, mainly Stage III compared adjuvant chemotherapy with
adjuvant radiotherapy [52,64], one trial evaluating 552 women mainly
Stage III compared two chemotherapy regimens (cisplatin/doxorubicin/
paclitaxel versus cisplatin/doxorubicin treatment) in women who had
all undergone adjuvant radiotherapy (GOG 184) [65], and one trial con-
tributed no data [51].
Overall and progression-free survivals were longer with adjuvant
chemotherapy compared with adjuvant radiotherapy [63]. In subgroup
analyses, the effects on survival in favor of chemotherapy were not
different for Stage III and IV, or Stage IIIA and IIIC. This evidence was
of moderate quality. Data from one trial showed that women receiving
adjuvant chemotherapy were more likely to experience hematological
and neurological adverse events and alopecia, and more likely to
discontinue treatment, than those receiving adjuvant radiotherapy
[63]. There was no statistically signiﬁcant difference in treatment-
related deaths between the chemotherapy and radiotherapy treatment
arms [63]. There was no clear difference in progression free survival be-
tween intervention groups in the one trial that compared cisplatin/
doxorubicin/paclitaxel versus cisplatin/doxorubicin [65].
A large trial evaluating adjuvant chemotherapy alone (six cycles
of carboplatin-paclitaxel) compared with chemotherapy during and
after radiation therapy (same schedule as used in PORTEC-3) for Stage
III− IV endometrial cancer (GOG 0258) has recently completed accrual
(804 patients) and results are expected in 2016.
Patients with presumed Stage III disease because of adnexal involve-
ment should have full surgical staging and expert pathologic examina-
tion of the specimen, as primary tumors of both the ovary and the
endometrium may be present. Management should be individualized,
and based on the stage of each tumor.
Patients with clinical Stage III endometrial carcinoma that is not
felt to be resectable by virtue of vaginal or parametrial extension are
best treated primarily by pelvic irradiation, with or without chemother-
apy [66]. Once therapy has been completed, exploratory laparotomy
should be considered for those patients whose disease now appears to
be resectable.
12. Stage IV
Patients with Stage IV disease based on intraperitoneal spread
beneﬁt from cytoreductive surgery only if there is no residual tumor
[67]. Neoadjuvant chemotherapy is an option, particularly if ascites is
present, and/or postoperative morbidity is considered likely [68]. After
surgery, platinum-based chemotherapy should be considered, based
on the GOG#122 trial cited above [28].
Patients with evidence of extra-abdominal metastases are usually
managed with systemic platinum-based chemotherapy, or hormonal
therapy if grade 1 and/or receptor positive. Combination chemotherapy
is the treatment of choice in advanced-stage disease as well as in re-
lapsed disease. The combinations of doxorubicin, cisplatin, and paclitax-
el (TAP) [69] and carboplatin and paclitaxel have been shown to be
most effective. The former is much more toxic.
Doxorubicinmonotherapy versus doxorubicin–cisplatin doublet has
been investigated in two randomized trials [70,71]. Both documented
superiority of the combination chemotherapy in terms of progression-
free and overall survival, with manageable toxicity. Doxorubicin–
cisplatin doublet versus doxorubicin–cisplatin–paclitaxel triplet was
tested in a phase III randomized trial [69]. The triplet regimen resulted
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men proved to be too toxic, with treatment-related deaths despite the
use of growth factors.
Carboplatin–paclitaxel doublet was tested in several phase II studies
in advanced-stage or relapsed disease, demonstrating a response rate
of 65%–75% and progression-free survival of about 14 months [72–74].
The interim results of the GOG-0209 trial, a noninferiority trial
comparing the combination of doxorubicin, cisplatin, and paclitaxel
(TAP) and G-CSF versus carboplatin and paclitaxel shows that
carboplatin and paclitaxel is not inferior to TAP [75]. The better tolera-
bility proﬁle of carboplatin–paclitaxel has lent credence to the use of
carboplatin and paclitaxel as the standard for adjuvant treatment in
Stage III and IV disease.
Pelvic radiotherapy in Stage IV disease may be used to provide local
tumor control and/or to treat symptoms such as vaginal bleeding or
pain from a local tumor mass, or leg edema due to lymph node involve-
ment. Palliation of brain or bone metastases can be effectively obtained
with short courses (1–5 fractions) of radiotherapy.
13. Targeted therapy
While surgery, radiotherapy, and cytotoxic therapy have improved
outcomes for patients with endometrial cancer, insights into pathogen-
esis of cancer have led to the development of drugs targetingmolecular
pathways vital to cancer cell survival including angiogenesis, DNA re-
pair, and apoptosis. The tumor suppressor gene PTEN (phosphate and
tensin homolog detected on chromosome 10) is important for normal
cellular function. Mutations in PTEN result in decreased apoptosis and
are found in up to 83% of endometrioid carcinomas of the uterus [76].
Decreased transcription due to the mutation leads to decreased phos-
phatidylinositol 3-kinase (PI3K) inhibition, increased activity of Akt,
and uncontrolled function of mTOR. Elevated activity of mTOR is seen
in a vast majority of endometrial cancers [77]. The mammalian target
of rapamycin (mTOR) is a kinase that regulates cell growth and apopto-
sis [78]. Temsirolimus, deforolimus, and everolimus are mTOR inhibi-
tors that have been tested as single agents in phase II studies. They
have been found to promote stable disease in 44% of patients with met-
astatic or recurrent cancer of the endometrium [79,80].
Development of a new blood supply (angiogenesis) is essential to
the development and maintenance of any tissue [81,82]. Diffusion of
nutrients over small distances is sufﬁcient for cellular function, but in
order for tumor growth to exceed 1 mm3 in volume, new vessels must
be recruited [82]. Tumor cells generate angiogenic factors that promote
new vessel formation and recruit supporting cells. The vessel density
and circulating tumor levels of many proangiogenic proteins such as
vascular endothelial growth factor (VEGF) and platelet-derived growth
factor (PDGF) are poor prognostic factors formany solid tumors, includ-
ing endometrial carcinoma [82]. VEGF is one of the best characterized
angiogenesis mediators [83,84]. Increased production of VEGF as well
as other growth factors is frequently observed in regions of hypoxia or
inﬂammation and in the presence of activated oncogenes or down-
regulated tumor suppressor genes [85,86]. Overexpression of VEGF
results in increased endothelial cell proliferation, decreased apoptosis,
and increased fenestration of endothelial cells [85–87]. VEGF overex-
pression has been shown to be associated with a poor prognosis in
most gynecologic malignancies including endometrial cancer [87]. The
role of drugs inhibiting angiogenesis pathways, such as bevacizumab
and tyrosine kinase inhibitors, is being studied in endometrial cancer.
In the ﬁrst phase II trial evaluating the activity and tolerability of
single-agent bevacizumab in 52 recurrent or persistent endometrial
cancers [88], seven patients (13.5%) had clinical responses and 21
(40.4%) had stable disease for 6 months.
Bevacizumab was added to adjuvant paclitaxel and carboplatin in a
phase II trial in patients with measurable disease [89]. Fourteen of the
15 patients were progression free at 6 months. A combination of
temsirolimus and bevacizumab showed a 24% response at the cost ofsigniﬁcant toxicity [90]. These ﬁrst studies of bevacizumab in advanced
and recurrent endometrial cancer need to be conﬁrmed in another
much larger phase II trial (GOG 86P).
Concerning tyrosine kinase inhibitors, a phase II trial evaluated the
efﬁcacy and safety of geﬁtinib in 26 patients with persistent/recurrent
endometrial cancer [91]. This treatment regimen was tolerable but
lacked sufﬁcient efﬁcacy to warrant further evaluation in this setting.
A phase II placebo-controlled randomized trial of chemotherapy plus
nintedanib (ENGOT-EN1) is to be initiated in Europe.
The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregu-
lated in endometrial cancer. Hormonal manipulation leads to response
in some patients, but resistance derived from PI3K pathway activation
has been documented. In a recent phase II trial of everolimus and
letrozole in women with recurrent disease, a clinical beneﬁt rate of
40% and objective response rate of 32% was documented [92].
Dysregulation of the cell cycle is one of the deﬁned hallmarks of can-
cer. The cyclin-dependent kinases (CDKs) have a crucial role in the reg-
ulation of the G1/S transition. Palbociclib is a reversible oral inhibitor of
CDK4/6 with acceptable toxicity proﬁle. A phase II randomized trial of
letrozole with and without palbociclib is being initiated in Europe.
Various groups have studied the use of HER2/neu-targeted therapies
in patients with aggressive endometrial cancer subtypes [93]. However,
a phase II study evaluating the efﬁcacy of trastuzumab alone for ad-
vanced or recurrent HER2-positive endometrial carcinoma reported
no major tumor responses among the 34 women ﬁnally enrolled [94].
A randomized phase II evaluation of carboplatin/paclitaxel with and
without trastuzumab in HER2/neu + patients with advance/recurrent
uterine serous papillary carcinoma is currently recruiting participants.
14. Special considerations
14.1. Diagnosis post hysterectomy
Diagnosis of endometrial carcinoma post hysterectomy can present
some management problems, particularly if the adnexae have not
been removed. This situationmost often arises following vaginal hyster-
ectomy for pelvic prolapse. Recommendations for further postoperative
therapy are based on known risk factors for extrauterine disease related
to the histologic grade and depth of myometrial invasion. Individuals
with grade 3 lesions, deep myometrial invasion, or LVSI are candidates
for additional surgery to remove the adnexae, or adjuvant external
beam pelvic radiation therapy. Patients with a grade 1 or 2 lesion with
minimal myometrial invasion and no LVSI involvement generally re-
quire no further therapy.
14.2. Medically inoperable patients
Morbid obesity and severe cardiopulmonary disease are the general
reasons a patient with endometrial carcinoma may be thought to be
medically inoperable. Uterine brachytherapy can achieve cure rates in
excess of 70% and may be combined with external beam radiotherapy
in the presence of prognostic factors suggesting a high risk of involved
nodes. Primary radiation therapy for clinical Stage I and II endometrial
adenocarcinoma provides disease control, with fewer than 16% of sur-
viving patients experiencing recurrence [95].
For patients with a well-differentiated lesion, contraindications to
general anesthesia, and who are unsuitable for radiotherapy, high-
dose progestins may be used.
14.3. Diagnosis in young women
The diagnosis of endometrial carcinoma during the reproductive
years should bemadewith caution, since this malignancy is uncommon
in women under 35 years, and grade 1 endometrial carcinoma may be
confused with severe atypical hyperplasia. In these women, consider-
ation should be given to an estrogen-related underlying condition
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such as megestrol acetate (160 mg/day) or medroxyprogesterone ace-
tate (500mg/day)maybe appropriate in these situations if preservation
of fertility is desired. The safety of such an approach has been reported
in a large number of studies, for grade 1 endometrial adenocarcinoma
and atypical hyperplasia only [96]. Equivocal lesions should be exam-
ined by an experienced pathologist. Although the literature describes
successful outcomes, fatal recurrences of endometrial cancer after a
conservative approach have been reported, and hysterectomy should
be recommended after childbearing has been completed.
Ovarian preservation, in patients with grade 1 intramucosal endo-
metrial adenocarcinoma, was not associated with an increase in
cancer-related mortality in the largest sample available [97].
15. Follow-up
The conventional reasons for follow-up of treated cancer patients
involve providing reassurance, diagnosing early recurrence, and
collecting data. One prospective [98] and several retrospective studies
[99–101] internationally have addressed follow-up. Overall, about 75%
of recurrences were symptomatic and 25% asymptomatic, and neither
recurrence-free nor overall survival were improved in asymptomatic
cases compared with those detected at clinical presentation. Most
(65%–85%) recurrenceswere diagnosedwithin 3 years of primary treat-
ment, and 40% of recurrences were local. The use of routine follow-up
Pap smears and chest X-rays is not cost-effective. In nonirradiated pa-
tients, a strong case can be made for regular follow-up to detect vaginal
recurrence at the earliest opportunity, given the high salvage rate fol-
lowing radiotherapy [102].
Two systematic reviews [103,104] documented evidence for the
utility of follow-up examinations, and concluded that follow-up should
be practical and directed by symptoms and pelvic examination, and that
frequency of follow-up visitsmay be reduced in low-risk patients. Given
the low risk of recurrence, vaginal cytology can be omitted, resulting in
reduced healthcare costs [105]. It appears that visual inspection is sufﬁ-
cient, since positive cytology is merely diagnosed in cases of symptom-
atic recurrence [100,106,107].
Patient counseling and follow-up should also acknowledge that
these patients are at risk of second cancers following their primary
endometrial cancer. The estimated incidence rate of Lynch syndrome
in an unselected endometrial cancer population is 3% − 6% [108].
Routine pathologic screening of mismatch repair deﬁciencies in the en-
dometrial cancer specimen, similar to colorectal cancer, has been advo-
cated [109]. A recent study showed that survivors of endometrial cancer
have a three-fold increased risk of a second cancer compared with a
matched population, mainly due to lifestyle factors and genetic suscep-
tibility [110].
16. Recurrence
Localized recurrences are managed preferentially by surgery, irradi-
ation, or a combination of the two, depending on the primary therapy.
Screening for distant metastases should be performed before deciding
on curative treatment. With an increasing number of patients managed
by surgery alone, radiotherapy provides an effective salvage treatment
in cases of vaginal or central pelvic recurrence. A combination of EBRT
and brachytherapy, preferably image guided, is usually required. Large
recurrences should be evaluated for excision, followed by radiotherapy.
Additional chemotherapy is being evaluated in an ongoing GOG trial.
Extended surgery may be justiﬁed, especially in patients who have
had prior radiation therapy. The results of pelvic exenteration in proper-
ly selected cases are similar to those obtained in cervical cancer.
Patients with non-localized recurrent tumors may be candidates for
progestin therapy (medroxyprogesterone acetate 50–100 mg three
times a day or megestrol acetate 80 mg 2–3 times a day). The progestin
therapy is continued as long as the disease is static or in remission.Maximum clinical response may not be apparent for 3 or more months
after initiating therapy. Platinum-based chemotherapy (cisplatinum
and doxorubicin, or carboplatin and paclitaxel) has been recommended
for patients with advanced or recurrent disease, not amenable to cure
by surgery and/or radiotherapy [28,72]. Targeted therapies are being in-
vestigated in several ongoing trials.
17. Recommendations for practice
(1) Preoperatively, a deﬁnitive tissue diagnosis must be obtained.
This helps to determine the surgical approach, and to differenti-
ate tumors at low and high risk of lymph node metastasis.
Imaging can be useful to determine depth of myometrial
invasion, cervical involvement, and lymph node enlargement.
Level of Evidence C
(2) Lymphadenectomy in clinical Stage I endometrial cancer has no
impact on overall or relapse-free survival. Level of Evidence A.
Outside clinical trials, lymphadenectomy should be performed
for staging only in high-risk cases. There is little evidence to sup-
port a therapeutic beneﬁt, but it should be used to select women
with positive nodes for adjuvant therapy. Level of Evidence C
(3) Adjuvant radiotherapy for women with Stage I endometrial can-
cer with low, intermediate, or high–intermediate risk features
has no impact on survival, although it reduces the rate of pelvic
recurrence. Level of Evidence A. Vaginal brachytherapy effec-
tively reduces the risk of vaginal relapse in patients with risk fac-
tors. Level of Evidence A. External beam radiotherapy should be
considered in patientswith positive nodes or advanced stage dis-
ease to ensure pelvic control. Level of Evidence B
(4) The addition of adjuvant chemotherapy to radiotherapy in pa-
tients with high-risk factors improves progression-free survival,
but an overall survival beneﬁt is unproven. Level of Evidence A
(5) Adjuvant chemotherapy for patients with early stage, high-risk
disease should only be considered within clinical trials.
(6) Chemotherapy is superior to whole abdominal radiation for pa-
tients with Stage III disease and abdominal disease with residual
nodules less than 2 cm diameter. Level of Evidence A
(7) Targeted therapy in endometrial cancer should only be consid-
ered within clinical trials.
(8) There is no evidence to support the use of adjuvant hormonal
therapy (progestogen). Level of Evidence A
(9) Patients with high-risk and advanced stage endometrial
cancer should be managed where possible by a gynecological
oncologist, working within a multidisciplinary team. Level of
Evidence A
(10) Patientswith endometrial cancer are frequently old and frail, and
this should be taken into account when prescribing adjuvant
therapy. Professional consensus
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